



Press release |

Market Authorization obtained in Portugal for the ¹⁸F-FDG IBA Synthera[®] Autoclave process

The Portuguese authorities have granted a ¹⁸F-FDG Market Authorization for the Synthera[®] synthesizer with final autoclaving process. Portugal is the 12th European country that has achieved its Market Authorization for the ¹⁸F-FDG process including an IBA Synthera[®] synthesizer. This important step was made possible thanks to the collaboration between IBA and the Institute of Nuclear Sciences Applied to Health (ICNAS) in Coimbra/PT.

“The possibility to autoclave the finished FDG product produced using Synthera[®] opens up new possibilities for radiopharmaceutical production centers. The end-user can choose between the aseptic preparation and the thermally sterilized product when using the Synthera[®] synthesizer in their process” says Cristiana Gameiro, IBA Product Manager - Synthera[®].

“As the Director of the ICNAS, I am extremely pleased with this success, which proves again that a solid and constructive partnership between the academia and the industry is powerful and beneficial for the advancement of science and technology. “ says Dr. Miguel Castelo Branco, Director of ICNAS

The Institute of Nuclear Sciences Applied to Health (ICNAS) is a new organic unit of the University of Coimbra, dedicated to the development of new techniques for both standard and clinical research in the field of biomedical radiation applications. The center operates the only public cyclotron in the country. The Marketing Authorization obtained for FDG will help to finance new science in the center within the fields of Oncology, Cardiology and Neuroscience.

Synthera[®] is a multi-purpose automated synthesizer for the production of ¹⁸F-FDG, other ¹⁸F-labeled compounds (¹⁸FCH, ¹⁸FLT, Na¹⁸F) as well as radiopharmaceuticals.

About IBA

IBA develops and markets leading-edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). Website: www.iba-worldwide.com

Contact IBA RadioPharma Solutions

Cristiana Gameiro, Ph.D.

Product Manager

Tel: +32 10 201276

E-mail: cristiana.gameiro@iba-group.com

March 19th, 2012